Sanofi India Posts ₹326.7 Cr Profit in FY25 Amid Revenue Dip, Recommends ₹48 Dividend

Sanofi India reported FY25 revenue from operations of ₹18,374 million, a decrease from ₹20,132 million in FY24.
However, Profit After Tax from Continuing Operations for FY25 rose to ₹3,267 million from ₹3,137 million in the previous fiscal.

Reader Takeaway: Profit grew on cost management and dividend hike; revenue decline due to contract loss remains a pressure point.

What just happened (today’s filing)

Sanofi India's Board of Directors met on February 25, 2026, to approve the audited financial results for the fiscal year ended December 31, 2025.
The company announced a revenue from operations of ₹18,374 million for FY25, a decline compared to ₹20,132 million in FY24.
Despite the revenue dip, the Profit After Tax from Continuing Operations saw a rise to ₹3,267 million from ₹3,137 million in the previous year.
The Board recommended a final dividend of ₹48 per equity share. Combined with the interim dividend, the total dividend payout for FY25 stands at ₹123 per share.

Why this matters

The results indicate a mixed performance, with cost efficiencies and potentially other factors driving profit growth despite lower sales. The significant dividend payout signals confidence from management, yet the revenue decline raises questions about future growth drivers.

The planned appointment of new directors, Mrs. Rajani Kesari and Ms. Sudipta Chakraborty, alongside the resignation of Mr. Rodolfo Hrosz, suggests potential strategic shifts or board restructuring.

The backstory (grounded)

Sanofi India's revenue has experienced a consistent decline over the last five years, with a CAGR of -9.2%. This trend was partly influenced by strategic decisions, such as the sale of its Ankleshwar manufacturing site to Zentiva in September 2019. This divestment was part of Sanofi's global strategy to focus on branded products. The current mention of an 'anticipated cessation of a contract with Zentiva' impacting export sales likely relates to the ongoing relationship or agreements stemming from this historical transaction. [cite:Filing]

What changes now

• Shareholder Returns: A higher total dividend of ₹123 per share for FY25 provides direct returns to shareholders.
• Board Composition: New directors with potentially fresh perspectives will join the board, while a key director departs.
• Operational Focus: The company's focus may shift further towards branded products and managing contract-related revenue fluctuations.
• Future Strategy: Management's approach to navigating revenue challenges and capitalising on profit improvements will be crucial.

Risks to watch

• Contract Cessation Impact: The anticipated cessation of a contract with Zentiva led to a ₹1,481 million decrease in export sales for FY25, and its future impact needs monitoring. [cite:Filing]
• Tax Authority Order: Sanofi India faces a tax demand of ₹2.37 crore for FY 2021-22 from the Commercial Tax Officer, Tamil Nadu, concerning Input Tax Credit (ITC) eligibility. The company plans to appeal this order.
• Trade Practice Allegations: The All India Chemists and Distributors Federation (AICDF) has raised concerns regarding Sanofi India's commercial circulars and trade policies, warning of potential regulatory intervention if disputes are not resolved.
• Past Regulatory Action: In 2015, Sanofi India was fined ₹3.04 crore by the Competition Commission of India (CCI) for collusive bidding related to vaccine tenders.
• New Labour Codes: The impact of implementing new Labour Codes on employee benefit obligations is yet to be assessed and will be evaluated upon notification of final rules. [cite:Filing]

Peer comparison

Sanofi India operates in a competitive pharmaceutical landscape alongside major players like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Lupin. While Sanofi focuses on specific therapeutic areas, the broader Indian pharmaceutical sector faces challenges in R&D intensity and innovation compared to global peers, highlighting the need for continuous strategic adaptation.

Context metrics (time-bound)

• Revenue from operations for FY25 stood at ₹18,374 million, down from ₹20,132 million in FY24. [cite:Filing]
• Profit After Tax from Continuing Operations for FY25 was ₹3,267 million, an increase from ₹3,137 million in FY24. [cite:Filing]
• Sanofi India's revenue has declined at a CAGR of -9.2% over the past 5 years (CY20-CY24).

What to track next

• Shareholder approval for the recommended final dividend at the ensuing 70th Annual General Meeting.
• Updates on the assessment of the impact of new Labour Codes on employee benefit obligations.
• Any further disclosures regarding the specific financial impact of the cessation of the contract with Zentiva on future export sales.
• Developments concerning the tax demand order from the Commercial Tax Officer and the AICDF's complaint.
• The strategic direction and performance under the newly appointed directors.